Actinium Pharmaceuticals, Inc. Class Action Lawsuit - ATNM

The filed complaint alleges that Actinium Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company’s data from the Phase 3 Sierra trial was unlikely to satisfy the FDA’s guidelines for the acceptance and approval of the Company’s targeted radiotherapy, Iomab-B BLA; (2) the additional analyses, including long-term follow-ups that purportedly demonstrated a trend towards improved Overall Survival that the Company provided to the FDA in an attempt to mitigate the Sierra Trial’s poor OS data were unlikely to satisfy the FDA’s guidelines for the acceptance and approval of the Company’s Iomab-B BLA; (3) as a result, the FDA would likely refuse to review the Iomab-B BLA or, if it did consider that BLA, that the application in its current form was unlikely to be approved; and (4), as a result, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

In order to be eligible to join the ATNM class action lawsuit, you must have incurred a loss on shares of Actinium purchased during the class period listed above.

If you suffered a loss in Actinium during the relevant time frame or pursuant to the relevant offering(s), you have until May 27, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.